Key Takeaways
·Monogram’s mBôS TKA System has received FDA clearance, but the company must demonstrate real-world clinical success and secure surgeon adoption to gain market traction.
·Unlike Stryker’s haptics-based Mako system, Monogram’s approach aims for greater autonomy, faster procedure times, and reduced surgeon fatigue – a potential game-changer if validated through clinical use.
·Monogram is leveraging clinical trials in India to generate key data for broader adoption, with Shalby Hospitals and Reliance Life Sciences playing a vital role in regulatory approval and market entry.
Monogram Technologies’ FDA clearance for its mBôS TKA System – a robotic-assisted total knee arthroplasty platform – signals its entry into a market dominated by well-established players like Stryker, Zimmer Biomet, and Smith & Nephew.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?